http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
송성훈,박진영,이행자,조홍식,장상목 동아대학교 환경문제연구소 1999 硏究報告 Vol.22 No.2
The phase transition phenomena and the phase separation phenomena of surfactants(SPES) are analyzed using QCA with resonant frequency and resonant resistance. The phase transition phenomena of SPES at 30℃ can be determined by measuring the resonant frequency and resonant resistance by lecithin coated on quartz crystal. The surfactants capacity of SPES can be analyzed by measuring the resonant frequency and resonant resistance of surfactants using QCA.
Hong, Sang‐,Mo,Park, Cheol‐,Young,Hwang, Dong‐,Min,Han, Kyung Ah,Lee, Chang Beom,Chung, Choon Hee,Yoon, Kun‐,Ho,Mok, Ji‐,Oh,Park, Kyong Soo,Park, Sung‐,Woo Blackwell Publishing Ltd 2017 Diabetes, obesity & metabolism Vol.19 No.5
<P><B>Aims</B></P><P>This trial consisted of a 24‐week multicentre, randomized, double‐blind, double‐dummy, active‐controlled study and a 52‐week open label extension study to assess the efficacy and safety of evogliptin, a novel dipeptidyl peptidase‐4 inhibitor, compared to sitagliptin in patients with type 2 diabetes who have inadequate glycaemic control with metformin alone.</P><P><B>Methods</B></P><P>Adult patients with type 2 diabetes mellitus (N = 222) with HbA1c 6.5% to 11% who were receiving stable doses of metformin (≥1000 mg/d) were randomized 1:1 to add‐on evogliptin 5 mg (N = 112) or sitagliptin 100 mg (N = 110) once daily for 24 weeks. The primary efficacy analysis consisted of a comparison of the change from baseline HbA1c at week 24. Non‐inferiority was concluded if the upper limit of the 2‐sided 95% confidence interval for the HbA1c difference between treatments was <0.35%.</P><P><B>Results</B></P><P>Mean changes in HbA1c following addition of evogliptin or sitagliptin were −0.59% and −0.65%, respectively. The between‐group difference was 0.06% (2‐sided 95% confidence interval, −0.10 to 0.22), demonstrating non‐inferiority. After the 52‐week treatment, evogliptin caused a persistently decreased level of HbA1c (−0.44% ± 0.65%, P < .0001). In general, both treatments were well tolerated, with incidences and types of adverse events comparable between the two groups. Hypoglycaemic events, mostly mild, were reported in 0.9% of patients treated with evogliptin and in 2.8% of patients treated with sitagliptin for 24 weeks.</P><P><B>Conclusions</B></P><P>Evogliptin 5 mg added to metformin therapy effectively improved glycaemic control and was non‐inferior to sitagliptin and well tolerated in patients with type 2 diabetes mellitus that was inadequately controlled by metformin alone.</P>
Presence of glioma stroma mesenchymal stem cells in a murine orthotopic glioma model.
Kim, Sang-Mok,Kang, Seok-Gu,Park, Na-Ri,Mok, Hyun-Su,Huh, Yong-Min,Lee, Su-Jae,Jeun, Sin-Soo,Hong, Yong-Kil,Park, Chun-Kun,Lang, Frederick F Springer Verlag 2011 Child's nervous system Vol.27 No.6
<P>High-grade gliomas are closely related to the mesenchymal phenotype which might be explained by unorthodox differentiation of glioma cancer stem cells (gCSCs). We reasoned that other non-neural stem cells, especially mesenchymal stem cells (MSCs), might play a role in expressing mesenchymal phenotype of high-grade gliomas. Thus we hypothesized that cells resembling MSCs exist in glioma specimens.</P>
Reductively Dissociable siRNA‐Polymer Hybrid Nanogels for Efficient Targeted Gene Silencing
Hong, Cheol Am,Kim, Jee Seon,Lee, Soo Hyeon,Kong, Won Ho,Park, Tae Gwan,Mok, Hyejung,Nam, Yoon Sung WILEY‐VCH Verlag 2013 Advanced functional materials Vol.23 No.3
<P><B>Abstract</B></P><P>A highly efficient approach for target‐specific gene silencing based on a reductively dissociable nanogel incorporating small interfering RNA (siRNA) crosslinked with linear polyethylenimine (LPEI) via disulfide bonds is presented. Thiol‐terminated siRNA at both 3′‐ends is electrostatically complexed with thiol‐grafted LPEI. The prepared siRNA/LPEI complex contains inter‐ and intramolecular linkages, generating a mutually crosslinked siRNA/LPEI nanogel (MCN) that exhibits excellent structural stability against the addition of heparin but is readily disintegrated to biologically active, monomeric siRNA upon exposure to reductive conditions. Accordingly, the highly condensed, stable MCN shows greatly enhanced cellular uptake and gene silencing efficiency compared to the siRNA/LPEI complexes without crosslinks or with only LPEI‐mediated crosslinks.</P>
Study Design and Outcomes of Korean Obstructive Lung Disease (KOLD) Cohort Study
Park, Tai Sun,Lee, Jae Seung,Seo, Joon Beom,Hong, Yoonki,Yoo, Jung-Wan,Kang, Byung Ju,Lee, Sei Won,Oh, Yeon-Mok,Lee, Sang-Do The Korean Academy of Tuberculosis and Respiratory 2014 Tuberculosis and Respiratory Diseases Vol.76 No.4
Background: The Korean Obstructive Lung Disease (KOLD) Cohort Study is a prospective longitudinal study of patients with chronic obstructive pulmonary disease (COPD), asthma, or other unclassified obstructive lung diseases. It was designed to develop new classification models and biomarkers that predict clinically relevant outcomes for patients with obstructive lung diseases. Methods: Patients over 18 years old who have chronic respiratory symptoms and airflow limitations or bronchial hyper-responsiveness were enrolled at 17 centers in South Korea. After a baseline visit, the subjects were followed up every 3 months for various assessments. Results: From June 2005 to October 2013, a total of 477 subjects (433 [91%] males; 381 [80%] diagnosed with COPD) were enrolled. Analyses of the KOLD Cohort Study identified distinct phenotypes in patients with COPD, and predictors of therapeutic responses and exacerbations as well as the factors related to pulmonary hypertension in COPD. In addition, several genotypes were associated with radiological phenotypes and therapeutic responses among Korean COPD patients. Conclusion: The KOLD Cohort Study is one of the leading long-term prospective longitudinal studies investigating heterogeneity of the COPD and is expected to provide new insights for pathogenesis and the long-term progression of COPD.